Siamab Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Siamab Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH238667D
  • |
  • Pages: 31
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Siamab Therapeutics Inc (Siamab Therapeutics), formerly Sialix Inc, is a biopharmaceutical company that focuses on the development of novel medicines targeting cancer-specific carbohydrate antigens. Its ST1 program targets a tumor associated carbohydrate antigen present in solid tumors. Siamab Therapeutics developed a technology platform that enables the discovery of large numbers of highly specific anti-TACA (tumor associated carbohydrate antigens) antibodies to kill cancer cells and also re-engage the immune system and overcome chemo-resistance.The company develops therapies in the areas of abnormal carbohydrates, glycans, ovarian, pancreatic, prostate, colon, breast and other solid tumors. Siamab Therapeutics is headquartered in Newton, Massachusetts, the US.

Siamab Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11

Siamab Therapeutics Raises USD2 Million in Venture Financing 12

Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13

Sialix Raises USD 2.5 Million In Venture Financing 14

Sialix Raises USD 4 Million In Series B Financing 15

Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16

Partnerships 17

Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17

Licensing Agreements 18

Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18

Siamab Therapeutics Inc-Key Competitors 19

Siamab Therapeutics Inc-Key Employees 20

Siamab Therapeutics Inc-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Product News 22

04/04/2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018 22

Clinical Trials 23

May 01, 2018: Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget 23

Jan 03, 2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase 2018 24

Oct 30, 2017: Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 25

Oct 03, 2017: Siamab Therapeutics Presents New Data at AACR's Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models 26

Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017 27

Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data On ST-1 at the AACR Annual Meeting 2017 28

Mar 21, 2017: Siamab Therapeutics to Present New Preclinical Data for Its Novel Antibodies and Antibody Drug Candidates at the American Association for Cancer Research Annual Meeting 2017 29

Mar 08, 2017: Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31

List of Figures

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Siamab Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11

Siamab Therapeutics Raises USD2 Million in Venture Financing 12

Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13

Sialix Raises USD 2.5 Million In Venture Financing 14

Sialix Raises USD 4 Million In Series B Financing 15

Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16

Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17

Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18

Siamab Therapeutics Inc, Key Competitors 19

Siamab Therapeutics Inc, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Siamab Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com